146 related articles for article (PubMed ID: 24158615)
21. Serum-level changes of vascular endothelial growth factor in children with infantile hemangioma after oral propranolol therapy.
Chen XD; Ma G; Huang JL; Chen H; Jin YB; Ye XX; Hu XJ; Lin XX
Pediatr Dermatol; 2013; 30(5):549-53. PubMed ID: 23909679
[TBL] [Abstract][Full Text] [Related]
22. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma.
Truong MT; Chang KW; Berk DR; Heerema-McKenney A; Bruckner AL
J Pediatr; 2010 Feb; 156(2):335-8. PubMed ID: 20105647
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of infantile parotid hemangioma with propranolol].
Liu XJ; Qin ZP; Tai MZ; Li KL; Ge CX
Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 May; 45(5):292-4. PubMed ID: 20654246
[TBL] [Abstract][Full Text] [Related]
24. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
25. Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns.
Parikh SR; Darrow DH; Grimmer JF; Manning SC; Richter GT; Perkins JA
JAMA Otolaryngol Head Neck Surg; 2013 Feb; 139(2):153-6. PubMed ID: 23429945
[TBL] [Abstract][Full Text] [Related]
26. Propranolol for isolated orbital infantile hemangioma.
Fay A; Nguyen J; Jakobiec FA; Meyer-Junghaenel L; Waner M
Arch Ophthalmol; 2010 Feb; 128(2):256-8. PubMed ID: 20142556
[No Abstract] [Full Text] [Related]
27. Propranolol for infantile hemangiomas.
Bagazgoitia L; Torrelo A; Gutiérrez JC; Hernández-Martín A; Luna P; Gutiérrez M; Baño A; Tamariz A; Larralde M; Alvarez R; Pardo N; Baselga E
Pediatr Dermatol; 2011; 28(2):108-14. PubMed ID: 21385205
[TBL] [Abstract][Full Text] [Related]
28. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Denoyelle F; Leboulanger N; Enjolras O; Harris R; Roger G; Garabedian EN
Int J Pediatr Otorhinolaryngol; 2009 Aug; 73(8):1168-72. PubMed ID: 19481268
[TBL] [Abstract][Full Text] [Related]
29. Propranolol treatment for infantile hemangioma: a case series of sixty-two patients.
Stringari G; Barbato G; Zanzucchi M; Marchesi M; Cerasoli G; Tchana B; Gritti A; Boccaletti V; Lombardi AA; Carano N
Pediatr Med Chir; 2016 Jun; 38(2):113. PubMed ID: 27345601
[TBL] [Abstract][Full Text] [Related]
30. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sagong M; Lim S; Chang W
Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
[TBL] [Abstract][Full Text] [Related]
31. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
[TBL] [Abstract][Full Text] [Related]
32. Management of adult onset orbital hemangioma by oral propranalol: a case report.
Murthy GJ; Goswami M
Orbit; 2012 Oct; 31(5):373-5. PubMed ID: 22877318
[TBL] [Abstract][Full Text] [Related]
33. Localized reticular pseudodrusen and their topographic relation to choroidal watershed zones and changes in choroidal volumes.
Alten F; Clemens CR; Heiduschka P; Eter N
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3250-7. PubMed ID: 23599330
[TBL] [Abstract][Full Text] [Related]
34. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Oct; 156(4):652-60. PubMed ID: 23891333
[TBL] [Abstract][Full Text] [Related]
35. Segregation of ophthalmoscopic characteristics according to choroidal thickness in patients with early age-related macular degeneration.
Switzer DW; Mendonça LS; Saito M; Zweifel SA; Spaide RF
Retina; 2012 Jul; 32(7):1265-71. PubMed ID: 22222760
[TBL] [Abstract][Full Text] [Related]
36. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study.
Zvulunov A; McCuaig C; Frieden IJ; Mancini AJ; Puttgen KB; Dohil M; Fischer G; Powell J; Cohen B; Ben Amitai D
Pediatr Dermatol; 2011; 28(2):94-8. PubMed ID: 21362031
[TBL] [Abstract][Full Text] [Related]
37. Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers.
Celik A; Tiryaki S; Musayev A; Kismali E; Levent E; Ergun O
J Drugs Dermatol; 2012 Jul; 11(7):808-11. PubMed ID: 22777220
[TBL] [Abstract][Full Text] [Related]
38. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
39. Propranolol for treatment of ulcerated infantile hemangiomas.
Saint-Jean M; Léauté-Labrèze C; Mazereeuw-Hautier J; Bodak N; Hamel-Teillac D; Kupfer-Bessaguet I; Lacour JP; Naouri M; Vabres P; Hadj-Rabia S; Nguyen JM; Stalder JF; Barbarot S;
J Am Acad Dermatol; 2011 May; 64(5):827-32. PubMed ID: 21353332
[TBL] [Abstract][Full Text] [Related]
40. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
